An ongoing dialogue on HIV/AIDS, infectious diseases,
August 10th, 2010
Curbside Consults: The Yin and the Yang
One of the simultaneously most enjoyable and exasperating aspects of being an Infectious Disease specialist is the large volume of “curbside” consultations we get from colleagues. For example, here’s this week’s talley — and it’s only Tuesday — done from memory and without systematically keeping track of emails, pages, phone calls, etc.: Duration of antibiotics […]
August 3rd, 2010
HIV Testing: NY Makes Progress; Massachusetts … Not So Much
From the office of New York Governor David Paterson: The Governor signed into law S.8227/A.11487, which will allow patients to agree to HIV testing as part of a general signed consent to medical care that remains in effect until it is revoked or expires. The bill will also, among other things: allow oral consent to […]
July 30th, 2010
Perinatal Transmission of HIV “Solved” — Now How Do We Pay For It?
Conspicuously absent from this year’s International AIDS Conference were major studies on prevention of maternal-to-child transmission. It could be that I just missed them, so I emailed a colleague who specializes in the area, and she concurred: Nope, did not see or hear major PMTCT updates at IAS. The thing is, this problem has been […]
July 6th, 2010
Torrid Tuesday
Some ID/HIV-related items for a sweltering summer day: Are the AIDS Drug Assistance Programs (ADAPs) in trouble? Certainly in some states they are, and this interview gives additional perspective. But I wonder — how much of this is HIV-specific, and how much is just the ongoing lousy economy. In other words, are other government-funded programs comparably stressed? […]
July 1st, 2010
RFA-AI-10-009, HIV Cure, and “Berlin Patient” Update
Interesting “RFA” (Request for Application, #RFA-AI-10-009) from Bethesda: The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH), National Institutes of Health (NIH), encourage grant applications from institutions/organizations to address the problem of HIV-1 persistence in HIV-1-infected persons treated with suppressive antiretroviral drug regimens… The goal of this […]
June 23rd, 2010
Combined HIV Antibody/Antigen Test Approved
From the FDA: The U.S. Food and Drug Administration today approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus (HIV)… The highly sensitive assay is intended to be used as an aid in the diagnosis of HIV-1/HIV-2 infection, including acute or primary HIV-1 infection. Since it actually detects the HIV-1 […]
June 16th, 2010
Another HIV Drug Development Program Bows Out
Last month, Avexa announced that they will not be going forward with their development of the investigational NRTI apricitabine. Now Myriad says its program to develop bevirimat is closing as well. The problems with these drugs — twice daily dosing with apricitabine, formulation and mixed responses with bevirimat — are not the real story here, since […]
June 11th, 2010
Plays at the (Culture) Plate
Some quick ID/HIV/other thoughts while we marvel in all that is Strasburgian: Did you know that HIV medication adherence improves over time? So much for “pill fatigue.” By the way, this anecdotally fits with my experience as well. And right now, the biggest reason for patients’ stopping their HIV meds is financial, usually due to loss of or […]
June 2nd, 2010
Screening for Anal Cancer and the World’s Worst Job
In Journal Watch AIDS Clinical Care, we published a simple case: Clinically stable HIV+ gay man, on HIV treatment; anal pap comes back with “atypical squamous cells of undetermined significance” (ASCUS). What to do with this result? Two experts weighed in, Howard Libman and Joel Gallant. In Howard’s thoughtful response, he acknowledges the limitations of the data […]
May 27th, 2010
HIV Treatment is Prevention!
The Lancet has just published a large prospective study demonstrating the protective effect of HIV treatment on the risk of viral transmission: 3381 couples were eligible for analysis … Only one of 103 genetically-linked HIV-1 transmissions was from an infected participant who had started ART, corresponding to transmission rates of 0·37 (95% CI 0·09—2·04) per 100 […]
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
